

TABLE OF CONTENTS

December 3, 2007

No. 2068

BUSINESS

- 1 Kyowa Hakko and Kirin Pharma Are a Perfect Match: Dr Matsuda
- Significant Synergism in the Field of Antibody Drug R&D
- 2 Takeda Creates New US Company for Therapeutic Antibody Research
- 3 ASKA Aims at ¥10 Billion Sales with Generics
- 3 ZERIA: Ethical Drugs Down, Consumer Healthcare Products Up
- 3 Fuso: First Operating, Ordinary Losses Since Listing
- 3 Wakamoto: Rysmon TG Shows Strong Growth
- 3 CMIC: Addition of CMIC SS CMO Boosts Sales, Profits
- 4 EPS: CRO, SMO Businesses Drives Sales, Profits
- 5 Diovan Remains No. 1 for 6th Month in a Row: Rep Track Survey

REGULATORY

- 6 Wider Range of Drugs to Be Re-Priced in Next Price Revision
- Premium Rates to Be Raised to Encourage Innovation
- Operating Profit Rates of 9.2-29.2% to Be Allowed Depending on Innovativeness
- Review of Industry's Pricing System Reform Proposals Postponed
- 7 (Proposed) Draft of the FY2008 NHI Drug Pricing System Reform
- 10 Re-Pricing of ARBs May Be Necessary: Mr Niwa
- Dispensing Fees Should Be Reshuffled to Promote Use of Generics
- Next NHI Price Revision May Hit Industry More Harshly Than Ever: Mr Takeda
- New Prescription Form May Drastically Increase Use of Generics
- 12 Council Calls For "Extraordinary NHI Drug Price Cuts"
- 12 Re-Pricing Runs Counter to the Promotion of Innovation: Dr Aoki
- 13 **REGULATORY NEWS IN BRIEF**
- Rocephin Approved for Once-Daily Administration in Children
- Nexavar Approved for Liver Cancer in the US: Bayer HealthCare, Onyx
- *Koroshio* Proposes Relaxation of Prescription Limitations for Psychotropic Drugs
- 14 **Commentary**
- Fight over Medical Fee/NHI Price Revision Rates Begin

R&D

- 14 Delay in Start of PI between Japan and West Reduced to 4-6 Months: AstraZeneca
- 16 JOINT-03 Study on Risedronate and Vitamin K2 to Start in 2008
- 16 **R&D NEWS IN BRIEF**
- IMMD Identifies 2nd Lead Compound in Collaboration with Shionogi
- Seikagaku Corp. to Start PII/III Trial of SI-6603
- Novartis Begins PII Study on QVA149

- Sanofi Pasteur Begins PII Trial of Cell Culture-based Influenza Vaccine
- Merck Serono to Develop AS703569 of Rigel Pharm. in Japan
- US Pharmas Lead Fight Against Infectious Diseases: PhARMA
- Ono Introduces Nisshin Food Products' Carcinogenicity Assessment System
- Insulin Glargine Reduces Incidence of MI: sanofi-aventis

SELF-MEDICATION

- 18 Kobayashi Stresses Legitimacy of Paltac-Kobashou Merger
- Planned Merger Goes Against Earlier Agreement with Suzuken: Suzuken
- Court Rejects Suzuken's Demand
- Sales Down 0.2% Despite Strong Sales of In-house Household Products
- 18 Rohto: Strong Growth in Japan and Abroad, Annual Sales to Exceed ¥100 Bil.

OPINION

- 19 **OPINION**
- Why Japanese Executives Are Grossly Underpaid: Philip Carrigan

TOPICS

- 19 **TOPICS**
- CareNet, Recruit Start Career Support Services for Doctors

MEDICAL DEVICES

20 MEDICAL DEVICE NEWS IN BRIEF

- Olympus: Record-High Sales, Profits
- Nipro: Sales of Medical Devices Up 18.1%
- Eiken Chemical: Sales Up 2.9%
- Miraca Holdings: Operating Profits Up 15% due to Cost-cutting
- Takara Bio: First Profits with Sales of ¥9,403 Mil.

GENERICS

21 GENERICS NEWS IN BRIEF

- JGPMMA Expands Its Organization, Activities
- Generics Switched Back to Original Drugs for Efficacy-Related Reasons in Most Cases
- New Prescription Form Will Enhance MRs' Influence over Pharmacists

MEDICAL FACILITIES & NURSING CARE

- 22 Gov't Appeals Asserting Legitimacy of *Kongo Shinryo*

22 MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF

- Pneumococcal Vaccination Rate Very Low in Japan: Banyu Seminar
- Recognition of Pneumococcal Vaccine Low among Elderly
- Adair Recommended for Long-term Management of Asthma in New Allergy GL
- Medicinal Narcotics Used in Cancer Pain Relief Cause no Dependence
- Self-injection of Enbrel Does Not Increase ADRs